FDA pursues shutdown recovery

Share this article:

Merck and Stallergenes are reclaiming their places in front of the FDA's advisory committees. The 16-day government shutdown scuttled the reviews of their allergy medications Grastek (Merck) and Oralair (Stallergenes), since they were not covered by the user fees that allowed the regulator to review and approve drugs while Congress froze government funding during the fight over healthcare reform.

The review committees are set for Dec. 12 (Merck) and Dec. 11 (Stallergenes).

Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.